Delighted to see our review paper on "Managing drug-induced QT prolongation in clinical practice" published in the @PMJ_BMJ.

This is a practical article that is relevant to all prescribers who prescribe medicines that can affect QT interval. https://pmj.bmj.com/content/early/2020/10/28/postgradmedj-2020-138661

We offer a pragmatic approach on initiating & monitoring
3 key factors to consider:
1) patient-related risk factors
2) potential risk and degree of QT prolongation associated with the proposed drug
3) co-prescribed medicines that could increase the risk of QT prolongation.

To support clinicians, we developed a simple algorithm to help guide clinical management in patients who are at risk of QT prolongation/TdP, those exposed to QT-prolonging medication or have QT prolongation.

@mmamas1973 @SABOURETCardio @DrMarthaGulati @Kfarooqi @ValleAlfonso @ALEX_MISCHIE @AndreasGevaert @ammozid @DLBHATTMD @biljana_parapid @AnastasiaSMihai @drkevinfernando @pabeda1 @iamritu @HeartOTXHeartMD @saia_francesco @GiuseppeGalati_ @Gerrythecynic @hvanspall @sarahhudsonuk

@cardiorespLTHT @LTHPharmacy @LeedsHospitals @ACNAPPresident @PJOnline_News @MedicineDean @savodoc @pcpa_org @nhsleeds @LeedsGp @LeedsGPPharmacy @kate_gatenby @krychtiukmd @KTamirisaMD @NikkiKF @EkateriniL @unileedscardio @JohnathanLaird @mirvatalasnag @proftomquinn @yaqoub_lina

@UKCPA @UKCPACardiac @bancccouncil @PCCS_UK @BcsPresident @BritishCardioSo @MSQGroup @MHRAgovuk @KnowYourPulse @UoL_LICAMM @UniversityLeeds @_Beth_Ward @LeedsMedicines @radcliffeCARDIO @WYHHealthyHeart @WYHpartnership